



Medline announces confidential submission of draft registration statement for proposed initial public offering

December 19, 2024

Northfield, Ill., Dec. 19, 2024 – Medline Inc. announced today that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC’s review process.

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Contacts

Karen King
Global Head Investor Relations
+1.847.247.7222, Karen.King@medline.com

Ben Fox
Vice President Corporate Communications
+1.262.271.5878, BeFox@medline.com